A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
Research output: Contribution to journal › Journal article › Research › peer-review
Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.
| Original language | English |
|---|---|
| Journal | New England Journal of Medicine |
| Volume | 362 |
| Issue number | 5 |
| Pages (from-to) | 416-26 |
| Number of pages | 11 |
| ISSN | 0028-4793 |
| DOIs | |
| Publication status | Published - 4 Feb 2010 |
ID: 34093028